ClinicalTrials.govpublic full text
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
advanced or metastatic breast cancer, breast cancer, hr positive, her2-low, her2-negative, trastuzumab deruxtecan (t-dxd; ds-8201a), anti-her2-antibody drug conjugate (adc), destiny-breast06, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 966118
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.